TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Investing.com

Anavex Life Sciences Crashes as EMA Setback Sparks Doubts on Lead Alzheimer Drug

Investing.com Logo Investing.com By Timothy Fries
Anavex Life Sciences Crashes as EMA Setback Sparks Doubts on Lead Alzheimer Drug

Anavex Life Sciences experienced a significant stock decline after receiving a negative trend vote from the European Medicines Agency regarding its Alzheimer's drug blarcamesine, causing shares to plummet approximately 50% in premarket trading.

Insights
QBTS.WS   negative

High-risk investment with slim chances of success in a competitive quantum computing landscape


AVXL   negative

Received a negative trend vote from EMA for its lead Alzheimer's drug, causing a 50% stock price drop, reducing market capitalization, and raising doubts about the drug's European approval prospects